A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial
Palabras clave :
Niraparib
Platinum based chemotherapy
BRCA status
Atezolizumab
Death-ligand 1 (PD-L1)
ADP-ribose
Anti-PD-L1/programmed cell death protein
Atezolizumab and NIraparib Treatment Association (ANITA)
Fecha de publicación :
2021
Nota editorial :
© IGCS and ESGO 2021. No commercial re-use.
Cita:
Sánchez-Lorenzo, M. L. (María Luisa); González-Martín, A. (Antonio); Colombo, N. (Nicoletta); et al. "A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial". International Journal of Gynecological Cancer. 31, 2021, 617 - 622
Aparece en las colecciones:
Estadísticas e impacto
0 citas en
0 citas en
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.